Elisabeth I. Heath, MD, FACP

Articles by Elisabeth I. Heath, MD, FACP

Key Unmet Needs in Prostate Cancer Management

ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD, FACP, Cedars-Sinai Samuel Oschin Cancer Center,Tian Zhang, MD, MHS, UT Southwestern Medical Center

March 22nd 2023

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

Recent Progress in the Prostate Cancer Treatment Landscape

ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD,Tian Zhang, MD, MHS, UT Southwestern Medical Center

March 22nd 2023

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps

ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD,Tian Zhang, MD, MHS, UT Southwestern Medical Center

March 3rd 2023

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

Breakthroughs in Imaging Modalities for Prostate Cancer

ByAlan H. Bryce, MD,Elisabeth I. Heath, MD, FACP,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Edwin M. Posadas, MD,Tian Zhang, MD, MHS, UT Southwestern Medical Center

March 3rd 2023

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

Metastatic CRPC Management: Future Directions in Care

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

January 9th 2023

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.

Addressing Barriers to Care in Metastatic Castration-Resistant Prostate Cancer

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

January 2nd 2023

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

Metastatic CRPC: Selecting Patients for Cabazitaxel or Radiotherapy

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

January 2nd 2023

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

Metastatic CRPC: Considering Use of Combination Cabazitaxel/Carboplatin

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

December 26th 2022

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.

Interpreting Data From the CARD Trial in Metastatic CRPC

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

December 19th 2022

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

The PROSELICA Trial: Cabazitaxel Dosing in Metastatic CRPC

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

December 19th 2022

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC

ByTanya B. Dorff, MD,Elisabeth I. Heath, MD, FACP

December 12th 2022

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.